Administration of an antibody to E-selectin in patients with septic shock
| Autor: | Robert J. Kahn, Gilberto Friedman, Michel Goldman, Mohammad Shahla, Jean Louis Vincent, Stanislaw Jankowski, Richard M. Rose |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors medicine.drug_class medicine.medical_treatment Pilot Projects Critical Care and Intensive Care Medicine Monoclonal antibody law.invention Pharmacokinetics law medicine Humans Weaning Prospective Studies Aged Chemotherapy biology Septic shock business.industry Hemodynamics Antibodies Monoclonal Middle Aged medicine.disease Shock Septic Intensive care unit Surgery Shock (circulatory) Anesthesia Injections Intravenous biology.protein Female Blood Gas Analysis medicine.symptom Antibody E-Selectin business |
| Zdroj: | Critical Care Medicine. 24:229-233 |
| ISSN: | 0090-3493 |
| DOI: | 10.1097/00003246-199602000-00008 |
| Popis: | Objectives : To determine the safety and pharmacokinetics of a murine monoclonal antibody to E-selectin in patients with newly developed septic shock. Design : Open-label, prospective, phase II pilot study with escalating doses of the antibody. Setting : Intensive care unit of a 900-bed university hospital. Patients : Nine patients who survived the first 24 hrs of septic shock. Interventions : In addition to standard therapy, an intravenous bolus of a murine monoclonal antibody to E-selectin, CY1787, was given at doses of 0.1 mg/kg In = 3), 0.33 mg/kg In = 3), and 1.0 mg/kg (n=3). Measurements and Main Results : CY1787 was well tolerated in all patients. Signs of shock resolved in all patients, and organ failure entirely reversed in eight patients. All patients survived the 28-day follow-up. Administration of CY1787 was associated with an early and brisk increase in Pao 2 /Fio 2 ratio (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|